Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: A detailed safety analysis

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 307-311

  O'Day, Steven J ^a   Agarwala, Sanjiv S ^b   Naredi, Peter ^c   Kass, Carrie L ^d   Gehlsen, Kurt R ^d   Glaspy, John ^e  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d Maxim Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Histamine; Immunotherapy; Interleukin 2; Medical oncology; Metastatic melanoma

Indexed keywords

HISTAMINE; INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CHILLS; FEMALE; FEVER; HISTAMINE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME; VASODILATION;

EID: 0037840341     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00014     Document Type: Article

References (17)

1. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997; 9:205-213.
2. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 2000; 6 (suppl 1):S8-S10.
3. Balch CM. A multifactorial analysis of melanoma. IV: Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126-134.
4. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 (suppl 1):S11-S14.
5. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228:307-319.
6. Margolin K. The clinical toxicities of high-dose interleukin-2. In: Atkins MB, Mier JW (editors): Therapeutic Applications of Interleukin-2. New York: Marcel Dekker; 1993, pp. 331-362.
7. Tagliaferri P, Barile C, Caraglia M, Guarrasi R, Morelli D, Ricciardi B, et al. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. Am J Clin Oncol 1998; 21:48-53.
8. Whitehead RP, Figlin R, Citron ML, Pfile J, Moldawer N, Patel D, et al. A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. J Immunother 1993; 13:117-121.
9. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6:669-678.
10. Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, Rankin EM. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol 1994; 5:179-181.
11. Hellstrand K, Hansson M, Hermodsson S. Adjuvant histamine in cancer immunotherapy. Semin Cancer Biol 2000; 10:29-39.
12. Hellstrand K, Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990; 92:379-389.
13. Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist U-H. Histamine in cancer immunotherapy. Scand J Clin Lab Invest 1997; 57:193-202.
14. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells: role of monocyte-derived reactive oxygen metabolites. J Immunol 1994; 153:4940-4947.
15. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-133.
16. Babe KS Jr, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE (editors): The Pharmacological Basis of Therapeutics, 9th edition. New York: McGraw-Hill; 1996, pp. 581-600.
17. Argarwala SS, Glaspy J, Whitman E, McMasters K, Deisseroth A, Gonzalez R, et al. Histamine dihydrochloride (hd) plus interleukin-2 (IL-2) in patients with metastatic melanoma (mm): Updated results of multicenter, randomized phase III study and an ongoing phase II study. Proc of Am Socy of Clin Oncol 2001, 20; 352a:1403.